Jonathan Baell

Company: Lyterian Therapeutics

Job title: Executive Director, Discovery Chemistry

Seminars:

Harnessing the Potential of Molecular Glues to Target & Degrade Proteins Across CNS Indications 1:01 pm

CNS disease targets possess the hallmarks of molecular glue’s ability to address hard-to-drug targets, furthered still with molecular glue’s smaller size being advantageous to penetrating the BBB. Join this workshop to debate the ability, current status, and major challenges to overcome to demonstrate the untapped potential of molecular glue applications to the CNS. Highlights include:…Read more

day: Pre-Conference Day